David Blum

Dr. David Blum


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2019 in Nature
Verified
Journal Article
Closed access
PDF file
CIChristina Ising
Christina Ising
CVCarmen Venegas
Carmen Venegas
SZShuangshuang Zhang
Shuangshuang Zhang
HSHannah Scheiblich
Hannah Scheiblich
SSSusanne V. Schmidt
Susanne V. Schmidt
MHMichael Thomas Heneka
Michael Thomas Heneka

1 October 2001 in Progress in Neurobiology
Verified
Journal Article
Closed access
DBDavid Blum
David Blum
STSakina Torch
Sakina Torch
NLNathalie Lambeng
Nathalie Lambeng
MNMarie-France Nissou
Marie-France Nissou
ABAlim-Louis Benabid
Alim-Louis Benabid
JVJean-Marc Verna
Jean-Marc Verna

1 February 2018 in Biomedical Journal
Verified
Journal Article
Open access
CLCyril Laurent
Cyril Laurent
LBLuc Buée
Luc Buée
DBDavid Blum
David Blum
Alzheimer's Disease (AD) is a chronic neurodegenerative disorder and the most common type of dementia (60-80% of cases). In 2016, nearly 44 million people were affected by AD or related dementia. AD is characterized by progressive neuronal damages leading to subtle and latter obvious decline in cognitive functions including symptoms such as memory loss or confusion, which ultimately require full-time medical care. Its neuropathology is defined by the extracellular accumulation of amyloid-β (Aβ) peptide into amyloid plaques, and intraneuronal neurofibrillary tangles (NFT) consisting of aggregated hyper- and abnormal phosphorylation of tau protein. The latter, identified also as Tau pathology, is observed in a broad spectrum of neurological diseases commonly referred to as "Tauopathies". Besides these lesions, sustained neuroinflammatory processes occur, involving notably micro- and astro-glial activation, which contribute to disease progression. Recent findings from genome wide association studies further support an instrumental role of neuroinflammation. While the interconnections existing between this innate immune response and the amyloid pathogenesis are widely characterized and described as complex, elaborated and evolving, only few studies focused on Tau pathology. An adaptive immune response takes place conjointly during the disease course, as indicated by the presence of vascular and parenchymal T-cell in AD patients' brain. The underlying mechanisms of this infiltration and its consequences with regards to Tau pathology remain understudied so far. In the present review, we highlight the interplays existing between Tau pathology and the innate/adaptive immune responses.

21 November 2005 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
Emmanuel BrouilletEmmanuel Brouillet
Emmanuel Brouillet
CJCarine Jacquard
Carine Jacquard
NBNicolas Bizat
Nicolas Bizat
DBDavid Blum
David Blum
Huntington's disease (HD) is a neurodegenerative disorder caused by a mutation in the gene encoding Huntingtin. The mechanisms underlying the preferential degeneration of the striatum, the most striking neuropathological change in HD, are unknown. Of those probably involved, mitochondrial defects might play an important role. The behavioural and anatomical similarities found between HD and models using the mitochondrial toxin 3‐nitropropionic acid (3NP) in rats and primates support this hypothesis. Here, we discuss the recently identified mechanisms of 3NP‐induced striatal degeneration. Two types of important factor have been identified. The first are the ‘executioner’ components that have direct roles in cell death, such as c‐Jun N‐terminal kinase and Ca2+‐activated protease calpains. The second are ‘environmental’ factors, such as glutamate, dopamine and adenosine, which modulate the striatal degeneration induced by 3NP. Interestingly, these recent studies support the hypothesis that 3NP and mutated Huntingtin have certain mechanisms of toxicity in common, suggesting that the use of 3NP might give new insights into the pathogenesis of HD. Research on 3NP provides additional proof that the neurochemical environment of a given neurone can determine its preferential vulnerability in neurodegenerative diseases.

5 November 2016 in Brain
Verified
Journal Article
Open access
PDF file
CLCyril Laurent
Cyril Laurent
GDGuillaume Dorothée
Guillaume Dorothée
SHStéphane Hunot
Stéphane Hunot
EMElodie Martin
Elodie Martin
YMYann Monnet
Yann Monnet
DBDavid Blum
David Blum
Alzheimer’s disease is characterized by the combined presence of amyloid plaques and tau pathology, the latter being correlated with the progression of clinical symptoms. Neuroinflammatory changes are thought to be major contributors to Alzheimer’s disease pathophysiology, even if their precise role still remains largely debated. Notably, to what extent immune responses contribute to cognitive impairments promoted by tau pathology remains poorly understood. To address this question, we took advantage of the THY-Tau22 mouse model that progressively develops hippocampal tau pathology paralleling cognitive deficits and reappraised the interrelationship between tau pathology and brain immune responses. In addition to conventional astroglial and microglial responses, we identified a CD8-positive T cell infiltration in the hippocampus of tau transgenic mice associated with an early chemokine response, notably involving CCL3. Interestingly, CD8-positive lymphocyte infiltration was also observed in the cortex of patients exhibiting frontemporal dementia with P301L tau mutation. To gain insights into the functional involvement of T cell infiltration in the pathophysiological development of tauopathy in THY-Tau22 mice, we chronically depleted T cells using anti-CD3 antibody. Such anti-CD3 treatment prevented hippocampal T cell infiltration in tau transgenic animals and reverted spatial memory deficits, in absence of tau pathology modulation. Altogether, these data support an instrumental role of hippocampal T cell infiltration in tau-driven pathophysiology and cognitive impairments in Alzheimer’s disease and other tauopathies.

1 April 2008 in Expert Review of Proteomics
Verified
Journal Article
Closed access
NSNicolas Sergeant
Nicolas Sergeant
ABAlexis Bretteville
Alexis Bretteville
MHMalika Hamdane
Malika Hamdane
MCMarie-Laure Caillet-Boudin
Marie-Laure Caillet-Boudin
PGPierre Grognet
Pierre Grognet
LBLuc Buée
Luc Buée
Microtubule-associated Tau proteins belong to a family of factors that polymerize tubulin dimers and stabilize microtubules. Tau is strongly expressed in neurons, localized in the axon and is essential for neuronal plasticity and network. From the very beginning of Tau discovery, proteomics methods have been essential to the knowledge of Tau biochemistry and biology. In this review, we have summarized the main contributions of several proteomic methods in the understanding of Tau, including expression, post-translational modifications and structure, in both physiological and pathophysiological aspects. Finally, recent advances in proteomics technology are essential to develop further therapeutic targets and early predictive and discriminative diagnostic assays for Alzheimer's disease and related disorders.